Onkologie. 2013:7(1):22-23

Role of denosumab in treating bone metastases

Jindřich Fínek
Onkologické a radioterapeutické oddělení, FN Plzeň

Denosumab is a fully human monoclonal antibody that specifically attacks the RANKL as the key osteoclast regulator. To date, denosumab

has been used to treat around 19,000 patients in various indications, with more than 11,000 having been treated in clinical trials

of oncological patients where it was tested in those with bone loss due to prostate and breast cancer therapies, for prevention of bone

events in generalized multiple myeloma and many solid tumours.

Keywords: bone event, bisphosphonates, denosumab

Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fínek J. Role of denosumab in treating bone metastases. Onkologie. 2013;7(1):22-23.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Capanna R, Coia LR, Coleman R, et al. eds. Textbook of Bone Metastases. Hoboken, NJ: Edition: John Wiley and Sons; 2005: 105.
    2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2(8): 584-593. Go to original source... Go to PubMed...
    3. Schulman K and Kohles J. Cancer 2007; 109: 2334-2342.
    4. GVD/Barber ISPOR 2008 Poster; Schulman 2007; Delea, et al. 2006.
    5. Saad F, et al. Long-term efficacy of zoledronic acid for prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Nat Cancer Inst 2004; 96(11): 879-882. Go to original source... Go to PubMed...
    6. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176. Go to original source... Go to PubMed...
    7. Podnos YD, Borneman TR, Koczywas M, Uman G, Ferrell BR. Symptom concerns and resource utilization in patients with lung cancer. J Pall Med 2007; 10(4): 899-903. Go to original source... Go to PubMed...
    8. David H. Henry Francois Goldwasser, Vera Hirsh, Vania Hungria, Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast andProstate Cancer) or Multiple Myeloma J Clin Oncol 2011: 29.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.